Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0014070 (encephalomyelitis)
 13,017 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

1. Brain homogenates of mice infected with the Theiler FA strain of mouse encephalomyelitis virus show marked inhibition of glucose phosphorylation. 2. A similar effect can be obtained by incubating normal brain homogenates with small amounts of ferrous sulfate. 3. Partially purified preparations of Theiler FA virus contain iron in amounts corresponding to their inhibitory effect on brain glycolysis. The virus preparations were purified by chemical fractionation and differential centrifugation and were dialyzed against potassium cyanide or pyrophosphate and potassium chloride for several days before they were analyzed for iron content. 4. The inhibitory effect of the virus preparations and of ferrous sulfate has been shown to be dependent on a heat-labile factor present in normal brain ("inactivating factor"). 5. The glycolytic activity of brain homogenates of mice infected with the Theiler FA virus can be restored by addition of a factor prepared from rabbit muscle extract. This "restoring factor" is non-dialyzable and is heat-labile. It has no hexokinase or phosphohexokinase activity. Its restoring activity is destroyed by the "inactivating factor" present in brain.
 ...
PMID:RELATION OF IRON SALTS TO INHIBITION OF GLYCOLYSIS BY THEILER FA VIRUS OF MOUSE ENCEPHALOMYELITIS. 1987 45

Microglial priming predisposes the brain to neurodegeneration and affects disease progression. The signal to switch from the quiescent to the primed state is unknown. We show that deleting the C3 convertase regulator complement receptor 1-related protein y (Crry) induces microglial priming. Mice that were double-knockout for Crry and either C3 or factor B did not show priming, demonstrating dependence on alternative pathway activation. Colocalization of C3b/iC3b and CR3 implicated the CR3/iC3b interaction in priming. Systemic lipopolysaccharide challenge overactivated primed microglia with florid expression of proinflammatory molecules, which were blocked by complement inhibition. Relevance for neurodegenerative disease is exemplified by human multiple sclerosis (MS) and by experimental autoimmune encephalomyelitis (EAE), a model of MS. In human MS, microglial priming was evident in perilesional white matter, in close proximity to C3b/iC3b deposits. EAE was accelerated and exacerbated in Crry-deficient mice, and was dependent on C activation. In summary, C3-dependent microglial priming confers susceptibility to other challenges. Our observations are relevant to progression in MS and other neurological diseases exacerbated by acute insults.
 ...
PMID:C3-dependent mechanism of microglial priming relevant to multiple sclerosis. 2227 10

Multiple sclerosis (MS) is the most common autoimmune demyelinating disease, affecting millions of individuals worldwide. In the last two decades, many therapeutic options for the treatment of MS have become available, however they are limited in terms of effectiveness and some remain plagued by safety issues. The currently available treatment options target relapsing remitting forms of MS and are not effective against the more progressive forms of the disease. These limitations highlight a significant unmet treatment need for MS. In experimental autoimmune encephalomyelitis (EAE) studies from our laboratory, we have previously shown, using a number of complement mutant and transgenic mice, that inhibition of the alternative complement pathway and the C3 convertase confers significant protection from disease. We report here that targeted inhibition of complement activation using complement receptor 2 (CR2)-conjugated inhibitors significantly attenuates EAE. Administration of CR2-Crry (blocks all complement pathways at C3 activation) and CR2-fH (specifically blocks the alternative pathway) just prior to and during the onset of EAE blocks progression of both acute and chronic disease. These data indicate that inhibition of complement may offer an effective therapeutic approach to treating both acute and chronic forms of demyelinating disease through blocking the alternative pathway or complement convertases.
 ...
PMID:Targeted inhibition of complement using complement receptor 2-conjugated inhibitors attenuates EAE. 2307 47